Artificial intelligence technologies are advancing the ability to conduct proactive screening to catch the warning signs of serious health conditions, like heart disease. With earlier detection of ...
InvestorsHub on MSN
Amarin highlights new REDUCE-IT analysis showing risk-weighted ApoB may improve cardiovascular risk detection (AMRN)
New REDUCE-IT data presented at EAS 2026 suggests risk-weighted apoB could better identify residual cardiovascular risk in ...
Cardiosense, a healthcare technology company focused on heart failure care, today announced that the U.S. Food & Drug Administration (FDA) has granted De Novo classification for its PCWP Analysis ...
For World Heart Day 2025, observed annually on Sept. 29 to raise public awareness of cardiovascular diseases and their prevention, Healthcare IT News has been tracking new technologies – and new ...
BOSTON--(BUSINESS WIRE)--Elucid has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its PlaqueIQ™ imaging analysis software to help physicians diagnose ...
WHIPPANY, N.J.--(BUSINESS WIRE)--The study design and baseline characteristics of FINE-HEART, a new prespecified, exploratory pooled analysis of three Phase III trials with finerenone 1, were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results